Company raises HK$9.89 billion (US$1.29 billion), with the proceeds to be used to support clinical trials and expand ...

In response to Fitch maintaining Hong Kong's AA- credit rating and stable outlook, the Hong Kong Special Administrative ...

Singapore biotech firm Mirxes began trading in Hong Kong on May 23 at a valuation exceeding US$1 billion. Read more at ...

In related news, Singapore-based pharmaceutical company Mirxes, which specializes in cancer treatment, also had a strong debut in Hong Kong on the same day. The company’s shares rose by 28% in morning ...

Theodore Shou, CEO of Yiyi Capital, discusses the recent strong performance of the IPO market in Hong Kong and says that the valuation premium between mainland China and Hong Kong stocks would narrow ...

Indian markets opened higher, driven by ITC and IT stocks, but concerns over foreign fund outflows and the U.S. fiscal ...

The NYSE debut is the first major IPO for a venture-backed digital-health company since the pandemic-era boom. The top lender, advised by law firm Paul Weiss, is in discussions to take over the ...

Which stocks will be in focus today including JSW Steel, Dhampur Sugar Mills, BSE, on which news will the market take action, ...

US markets mixed, Dow closed flat after slipping 230 points from day's high, Nasdaq closed 53 points stronger despite ...

The Chinese drugmaker raised HK$9.74 billion, equivalent to US$1.25 billion, in net proceeds, making it one of Hong Kong's largest IPOs so far this year. The stock was priced at HK$44.05 per share, ...

Shares of Jiangsu Hengrui Pharmaceuticals soared Friday morning, as more companies seek to tap Hong Kong’s capital markets.

Jiangsu Hengrui Pharmaceuticals Co (HK:1276) made a powerful entrance on the Hong Kong Stock Exchange on Friday, with shares ...